Role of Montelukast in Asthma and Allergic rhinitis patients

Abstract

Objectives: Our objective was to evaluate the effect of Montelukast on the symptoms of asthma and allergic rhinitis (AR), assess its effect on the individual quality of life (QoL), and estimate the proportion of participants having adverse effects.
 Methods: This prospective, open-label study conducted at Dow University of Health Sciences, Ankle Saria Hospital and Sindh Government Hospital Liaquatabad, Karachi, from August 2018 to September 2019, included patients aged >18 years with a clinical diagnosis of Asthma, AR, or both. Patients were given a 10 mg Montelukast tablet each day and then called for follow-up in the fourth week, where the questions related to the improvement in the symptoms of asthma or AR were asked. Patients were also asked about the improvement in QoL and any adverse effects.
 Results: A total of 694 patients were registered of which 138(19.8%) had AR, 294(42.4%) had asthma, while 273(39.3%) had both. Mean age was 41.1±14.63 years and 352 (50.7%) were male and 342(49.3%) were females. On a follow-up visit, there was a sufficient improvement in 351 asthmatics (63.9%), and 288 patients with AR (70.1%) overall, strong or marked improvement in the day (n=342,62.3%) and night time (n=331,60.3%) asthma symptoms. Overall improvements in QoL were very good or good in 419 patients. Montelukast was well-tolerated here with adverse effects (like abdominal discomfort, fever, fatigue, headache, rash, and upper respiratory tract symptoms) seen in 125 patients (18.01%).
 Conclusion: Montelukast was very effective in improving the symptoms and QoL of the individuals suffering from asthma and/or AR.
 doi: https://doi.org/10.12669/pjms.36.7.2657
 How to cite this:Zuberi FF, Haroon MA, Haseeb A, Khuhawar SM. Role of Montelukast in Asthma and Allergic rhinitis patients. Pak J Med Sci. 2020;36(7):---------. doi: https://doi.org/10.12669/pjms.36.7.2657
 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Role of Leukotriene Antagonists in the Treatment of Asthma Exacerbations

“…In the study,125 patients (18.01%) had one or more adverse effects. The adverse events were headache (5.6%), fever (2.2%), fatigue (5.2%), abdominal discomfort (2.6%), URTI (1.4%), rash (1%) [14].…”

Exploring the influence of the microbiome on the pharmacology of anti-asthmatic drugs

“…Montelukast can be used as an adjunct to ICS therapy or as an alternate prophylactic treatment for asthmatics (Zuberi et al 2020 ). It improves long-term asthma management when combined with ICS (Zuberi et al 2020 ) and appears to be very effective in treating some phenotypes of asthma, such as exercise-induced asthma and asthma linked with rhinitis (Philip et al 2004 ).…”

“…Montelukast can be used as an adjunct to ICS therapy or as an alternate prophylactic treatment for asthmatics (Zuberi et al 2020 ). It improves long-term asthma management when combined with ICS (Zuberi et al 2020 ) and appears to be very effective in treating some phenotypes of asthma, such as exercise-induced asthma and asthma linked with rhinitis (Philip et al 2004 ). Although less effective than regular low-dose ICS therapy, montelukast can be used as monotherapy for individuals who either have experienced adverse reactions to ICS, patients with concurrent allergic rhinitis or for whom inhaled therapy is impractical (Joos et al 2008 ).…”

Clinical study on the treatment of moderate to severe persistent allergic rhinitis by posterior nasal nerve combined with anterior ethmoid neurotomy

“…rhinitis, as a common otorhinolaryngologic disease, occurs at any age and has a complicated pathogenesis. 1 It occurs all over the world with an increasing incidence in recent years. It has been pointed out in relevant studies that allergic rhinitis is a chronic noninfectious inflammation, and in severe cases, it will affect the daily life and work of patients.…”